Table 5 Referral patterns of patients receiving cardiotoxic chemotherapy agents from oncology clinic to cardio-oncology or cardiology clinic

Race

p = 0.66

 Black

33 (47.1%)

35 (44.3%)

 White

21 (30.0%)

20 (25.3%)

 Hispanic

14 (20.0%)

19 (27.9%)

 Others

2 (2.9%)

5 (6.3%)

Age at diagnosis (median, [IQR])

61 (51, 68)

56 (50, 64)

p = 0.55

Gender

p = 0.68

 Male

9 (12.9%)

12 (15.2%)

 Female

61 (87.1%)

67 (84.8%)

Insurance

p = 0.18

 Private insurance

39 (55.7%)

39 (49.4%)

 Medicare

26 (37.1%)

25 (31.6%)

 Medicaid

2 (2.9%)

3 (3.8%)

 No insurance

3 (4.3%)

12 (15.2%)

Income by ZIP code

p = 0.039

 Quartile 1

11 (15.7%)

26 (32.9%)

 Quartile 2

17 (24.3%)

18 (22.8%)

 Quartile 3

23 (32.9%)

15 (19.0%)

 Quartile 4

19 (27.1%)

20 (25.3%)

 HTN

52 (74.3%)

32 (40.5%)

p < 0.0001

 HLD

25 (35.7%)

23 (29.1%)

p = 0.39

 CAD

12

0

p = 0.0006

 Arrhythmia

11

4

p = 0.035

 DM

22 (31.4%)

17 (21.5%)

p = 0.17

 Smoking

27 (38.6%)

34 (42.0%)

p = 0.67

 FH

20 (28.6%)

20 (24.7%)

p = 0.59

 Age > 65

20 (28.6%)

14 (17.7%)

p = 0.12

 Coronary stents

4

0

p = 0.13

 Cardiac surgery

1

0

p = 1.00

 Beta blocker

13

12

p = 0.63

 ACEI/ARB

26

19

p = 0.08

 Diuretic

5

5

p = 0.84

 Hydralazine

1

1

p = 0.93

 Nitrate

1

1

p = 0.93

 MRA

0

0

p = 1

 CCB

8

9

p = 0.99

 Antiarrhythmic

0

0

p = 1

 Aspirin

14

10

p = 0.22

 Statin

17

11

p = 0.11

Cancer type

p = 0.005

 Breast cancer

59 (84.3%)

52 (64.3%)

 Other cancer

11 (15.7%)

29 (35.8%)

Cancer stage

p = 0.07

 Stage 1

8 (11.4%)

4 (4.9%)

 Stage 2

38 (54.3%)

33 (40.7%)

 Stage 3

11 (15.7%)

18 (22.2%)

 Stage 4

13 (18.6%)

26 (32.1%)

Chemotherapy

p = 0.036

 Doxorubicin

22 (31.4%)

42 (51.9%)

 Herceptin

40 (57.1%)

34 (42.0%)

 Doxorubicin and herceptin

8 (11.4%)

5 (6.2%)